Pharmaceutical Drug Delivery Market by Route of Administration (Oral Drug Delivery, Pulmonary Drug Delivery, Injectable Drug Delivery, Ocular Drug Delivery, Nasal Drug Delivery, Topical Drug Delivery, Implantable Drug Delivery, Transmucosal Drug Delivery), Application (Infectious Diseases, Cancer, Cardiovascular Diseases, Diabetes, Respiratory Diseases, Central Nervous System Disorders, and Autoimmune Diseases), End-User, and Geography – Global Forecast up to 2026
Pharmaceutical drug delivery is referred to a device that is commonly used for the control or target drug delivery of a variety of therapeutic agents to treat several numbers of diseases or for better improvement in the health of the patients. Drug delivery systems are medical equipment utilized to infuse drugs or chemicals into the body and also used to stimulate drug absorption, efficiency, and experience of the patient. Rapidly increasing infectious and chronic diseases worldwide and growing research & developments in drug delivery are the major reasons responsible for the growth in the pharmaceutical drug delivery market. But somehow, the growth in incidences of drug recall and drug failures are limiting the market growth. The Pharmaceutical Drug Delivery Market is anticipated to grow at a CAGR of 4.6% during the forecast period of 2020-2026.
Research Methodology:
The pharmaceutical drug delivery market has been analyzed by utilizing the optimum combination of secondary sources and in-house methodology, along with an irreplaceable blend of primary insights. The real-time assessment of the market is an integral part of our market sizing and forecasting methodology. Our industry experts and panel of primary participants have helped in compiling relevant aspects with realistic parametric estimations for a comprehensive study. The participation share of different categories of primary participants is given below:
Pharmaceutical Drug Delivery Market, by Route of Administration
In the application market, pharmaceutical drug delivery is majorly applied in cancer diseases. The key reason is the increasing incidence of cancer all over the world and the increasing need for the latest and advanced therapeutics for cancer treatment, which is giving the majority for this segment in the application.
As per the end-user, the pharmaceutical drug delivery market is majorly divided into hospitals, home care settings, ambulatory survey centers, and diagnostic centers. The huge number of inpatient and outpatient visits to hospitals and the necessity of a huge amount of drugs and the respective delivery devices to render service to a large number of patients in the hospital are the reasons responsible for the largest share of hospitals in this market.
Geographically, the pharmaceutical drug delivery market is majorly segregated into North America, Europe, Asia Pacific, and the Rest of the World. North America is happening to hold a significant share in the market due to the encouraging government initiatives for the development of drug delivery technologies, increasing pharmaceutical investment with the rising cases of cancer, and emerging advanced technology in oral drug delivery in this region.
Some other aspects which are enhancing the pharmaceutical drug delivery market growth globally are rapidly increasing numbers of infectious and chronic diseases. This may result in growth in the biologics market, which is significantly stimulating global market growth. However, the risk involved in injectable drug delivery, such as needle stick injury, is hampering the market growth.
Some of the companies’ profiles are provided in the Pharmaceutical Drug Delivery Market-F. Hoffman-La Roche, Bayer AG, Pfizer, GlaxoSmithKline plc, Inc., Novartis AG, 3M Company, Becton, Dickinson and Company, Sanofi, Merck & Co., Inc., Antares Pharma, Inc., AbbVie, Amgen, Johnson & Johnson, Inc, AstraZeneca, Eli Lilly and Company, Gilead Sciences, Inc., Teva Pharmaceuticals, Boehringer Ingelheim, Bristol-Myers Squibb, and Genmab A/S.
Thus, advanced developments in pharmaceutical drug delivery, such as utilization to serve through diagnostic tools, are supporting the market growth further. This report provides the emerging developments in the drug delivery industry.
Research Methodology:
The pharmaceutical drug delivery market has been analyzed by utilizing the optimum combination of secondary sources and in-house methodology, along with an irreplaceable blend of primary insights. The real-time assessment of the market is an integral part of our market sizing and forecasting methodology. Our industry experts and panel of primary participants have helped in compiling relevant aspects with realistic parametric estimations for a comprehensive study. The participation share of different categories of primary participants is given below:
Pharmaceutical Drug Delivery Market, by Route of Administration
- Oral Drug Delivery
- Pulmonary Drug Delivery
- Injectable Drug Delivery
- Ocular Drug Delivery
- Nasal Drug Delivery
- Topical Drug Delivery
- Implantable Drug Delivery
- Transmucosal Drug Delivery
- Infectious Diseases
- Cancer
- Cardiovascular Diseases
- Diabetes
- Respiratory Diseases
- Central Nervous System Disorders
- Autoimmune Diseases
- Hospitals
- Home Care Settings
- Ambulatory Survey Centers
- Diagnostic Centers
- North America
- Europe
- Asia Pacific
- Rest of the World
In the application market, pharmaceutical drug delivery is majorly applied in cancer diseases. The key reason is the increasing incidence of cancer all over the world and the increasing need for the latest and advanced therapeutics for cancer treatment, which is giving the majority for this segment in the application.
As per the end-user, the pharmaceutical drug delivery market is majorly divided into hospitals, home care settings, ambulatory survey centers, and diagnostic centers. The huge number of inpatient and outpatient visits to hospitals and the necessity of a huge amount of drugs and the respective delivery devices to render service to a large number of patients in the hospital are the reasons responsible for the largest share of hospitals in this market.
Geographically, the pharmaceutical drug delivery market is majorly segregated into North America, Europe, Asia Pacific, and the Rest of the World. North America is happening to hold a significant share in the market due to the encouraging government initiatives for the development of drug delivery technologies, increasing pharmaceutical investment with the rising cases of cancer, and emerging advanced technology in oral drug delivery in this region.
Some other aspects which are enhancing the pharmaceutical drug delivery market growth globally are rapidly increasing numbers of infectious and chronic diseases. This may result in growth in the biologics market, which is significantly stimulating global market growth. However, the risk involved in injectable drug delivery, such as needle stick injury, is hampering the market growth.
Some of the companies’ profiles are provided in the Pharmaceutical Drug Delivery Market-F. Hoffman-La Roche, Bayer AG, Pfizer, GlaxoSmithKline plc, Inc., Novartis AG, 3M Company, Becton, Dickinson and Company, Sanofi, Merck & Co., Inc., Antares Pharma, Inc., AbbVie, Amgen, Johnson & Johnson, Inc, AstraZeneca, Eli Lilly and Company, Gilead Sciences, Inc., Teva Pharmaceuticals, Boehringer Ingelheim, Bristol-Myers Squibb, and Genmab A/S.
Thus, advanced developments in pharmaceutical drug delivery, such as utilization to serve through diagnostic tools, are supporting the market growth further. This report provides the emerging developments in the drug delivery industry.
- This report of the pharmaceutical drug delivery market discusses the present state, innovations, and future needs of the market end-users.
- This study examines the various categories of drug delivery, divided by market shares of the key manufacturers and acquisitions, mergers, and alliances by vendors and global organizations.
- This research further analyses the stringent environment and the involved technology, including the new trends and developments.
- The pharmaceutical drug delivery market also presents the major vendors of the industry.
1. EXECUTIVE SUMMARY
2. INDUSTRY OUTLOOK
2.1. Industry Overview
2.2. Industry Trends
3. MARKET SNAPSHOT
3.1. Market Definition
3.2. Market Outlook
3.2.1. PEST Analysis
3.2.2. Porter Five Forces
3.3. Related Markets
4. MARKET CHARACTERISTICS
4.1. Market Evolution
4.2. Market Trends and Impact
4.3. Advantages/Disadvantages of Market
4.4. Regulatory Impact
4.5. Market Offerings
4.6. Market Segmentation
4.7. Market Dynamics
4.7.1. Drivers
4.7.2. Restraints
4.7.3. Opportunities
4.8. DRO - Impact Analysis
5. ROUTE OF ADMINISTRATION: MARKET SIZE & ANALYSIS
5.1. Overview
5.2. Oral Drug Delivery
5.3. Pulmonary Drug Delivery
5.4. Injectable Drug Delivery
5.5. Ocular Drug Delivery
5.6. Nasal Drug Delivery
5.7. Topical Drug Delivery
5.8. Implantable Drug Delivery
5.9. Transmucosal Drug Delivery
6. APPLICATION: MARKET SIZE & ANALYSIS
6.1. Overview
6.2. Infectious Diseases
6.3. Cancer
6.4. Cardiovascular Diseases
6.5. Diabetes
6.6. Respiratory Diseases
6.7. Central Nervous System Disorders
6.8. Autoimmune Diseases
7. END-USER: MARKET SIZE & ANALYSIS
7.1. Overview
7.2. Home Care Settings
7.3. Ambulatory Survey Centers
7.4. Diagnostic Centers
8. GEOGRAPHY: MARKET SIZE & ANALYSIS
8.1. Overview
8.2. North America
8.3. Europe
8.4. Asia Pacific
8.5. Rest of the World
9. COMPETITIVE LANDSCAPE
9.1. Competitor Comparison Analysis
9.2. Market Developments
9.2.1. Mergers and Acquisitions, Legal, Awards, Partnerships
9.2.2. Product Launches and execution
10. VENDOR PROFILES
10.1. F. Hoffman-La Roche
10.1.1. Overview
10.1.2. Financials
10.1.3. Products & Services
10.1.4. Recent Developments
10.1.5. Business Strategy
10.2. Bayer AG
10.2.1. Overview
10.2.2. Financials
10.2.3. Products & Services
10.2.4. Recent Developments
10.2.5. Business Strategy
10.3. Pfizer
10.3.1. Overview
10.3.2. Financials
10.3.3. Products & Services
10.3.4. Recent Developments
10.3.5. Business Strategy
10.4. GlaxoSmithKline plc, Inc
10.4.1. Overview
10.4.2. Financials
10.4.3. Products & Services
10.4.4. Recent Developments
10.4.5. Business Strategy
10.5. Novartis AG
10.5.1. Overview
10.5.2. Financials
10.5.3. Products & Services
10.5.4. Recent Developments
10.5.5. Business Strategy
10.6. 3M Company
10.6.1. Overview
10.6.2. Financials
10.6.3. Products & Services
10.6.4. Recent Developments
10.6.5. Business Strategy
10.7. Becton, Dickinson and Company
10.7.1. Overview
10.7.2. Financials
10.7.3. Products & Services
10.7.4. Recent Developments
10.7.5. Business Strategy
10.8. Sanofi
10.8.1. Overview
10.8.2. Financials
10.8.3. Products & Services
10.8.4. Recent Developments
10.8.5. Business Strategy
10.9. Merck & Co., Inc
10.9.1. Overview
10.9.2. Financials
10.9.3. Products & Services
10.9.4. Recent Developments
10.9.5. Business Strategy
10.10. Antares Pharma, Inc
10.10.1. Overview
10.10.2. Financials
10.10.3. Products & Services
10.10.4. Recent Developments
10.10.5. Business Strategy
11. COMPANIES TO WATCH
11.1. AbbVie
11.1.1. Overview
11.1.2. Products & Services
11.1.3. Business Strategy
11.2. Amgen
11.2.1. Overview
11.2.2. Products & Services
11.2.3. Business Strategy
11.3. Johnson & Johnson, Inc
11.3.1. Overview
11.3.2. Products & Services
11.3.3. Business Strategy
11.4. AstraZeneca
11.4.1. Overview
11.4.2. Products & Services
11.4.3. Business Strategy
11.5. Eli Lilly and Company
11.5.1. Overview
11.5.2. Products & Services
11.5.3. Business Strategy
11.6. Gilead Sciences, Inc
11.6.1. Overview
11.6.2. Products & Services
11.6.3. Business Strategy
11.7. Teva Pharmaceuticals
11.7.1. Overview
11.7.2. Products & Services
11.7.3. Business Strategy
11.8. Boehringer Ingelheim
11.8.1. Overview
11.8.2. Products & Services
11.8.3. Business Strategy
11.9. Bristol-Myers Squibb
11.9.1. Overview
11.9.2. Products & Services
11.9.3. Business Strategy
11.10. Genmab A/S
11.10.1. Overview
11.10.2. Products & Services
11.10.3. Business Strategy
12. ANALYST OPINION
13. ANNEXURE
13.1. Report Scope
13.2. Market Definitions
13.3. Research Methodology
13.3.1. Data Collation and In-house Estimation
13.3.2. Market Triangulation
13.3.3. Forecasting
13.4. Report Assumptions
13.5. Declarations
13.6. Stakeholders
13.7. Abbreviations
2. INDUSTRY OUTLOOK
2.1. Industry Overview
2.2. Industry Trends
3. MARKET SNAPSHOT
3.1. Market Definition
3.2. Market Outlook
3.2.1. PEST Analysis
3.2.2. Porter Five Forces
3.3. Related Markets
4. MARKET CHARACTERISTICS
4.1. Market Evolution
4.2. Market Trends and Impact
4.3. Advantages/Disadvantages of Market
4.4. Regulatory Impact
4.5. Market Offerings
4.6. Market Segmentation
4.7. Market Dynamics
4.7.1. Drivers
4.7.2. Restraints
4.7.3. Opportunities
4.8. DRO - Impact Analysis
5. ROUTE OF ADMINISTRATION: MARKET SIZE & ANALYSIS
5.1. Overview
5.2. Oral Drug Delivery
5.3. Pulmonary Drug Delivery
5.4. Injectable Drug Delivery
5.5. Ocular Drug Delivery
5.6. Nasal Drug Delivery
5.7. Topical Drug Delivery
5.8. Implantable Drug Delivery
5.9. Transmucosal Drug Delivery
6. APPLICATION: MARKET SIZE & ANALYSIS
6.1. Overview
6.2. Infectious Diseases
6.3. Cancer
6.4. Cardiovascular Diseases
6.5. Diabetes
6.6. Respiratory Diseases
6.7. Central Nervous System Disorders
6.8. Autoimmune Diseases
7. END-USER: MARKET SIZE & ANALYSIS
7.1. Overview
7.2. Home Care Settings
7.3. Ambulatory Survey Centers
7.4. Diagnostic Centers
8. GEOGRAPHY: MARKET SIZE & ANALYSIS
8.1. Overview
8.2. North America
8.3. Europe
8.4. Asia Pacific
8.5. Rest of the World
9. COMPETITIVE LANDSCAPE
9.1. Competitor Comparison Analysis
9.2. Market Developments
9.2.1. Mergers and Acquisitions, Legal, Awards, Partnerships
9.2.2. Product Launches and execution
10. VENDOR PROFILES
10.1. F. Hoffman-La Roche
10.1.1. Overview
10.1.2. Financials
10.1.3. Products & Services
10.1.4. Recent Developments
10.1.5. Business Strategy
10.2. Bayer AG
10.2.1. Overview
10.2.2. Financials
10.2.3. Products & Services
10.2.4. Recent Developments
10.2.5. Business Strategy
10.3. Pfizer
10.3.1. Overview
10.3.2. Financials
10.3.3. Products & Services
10.3.4. Recent Developments
10.3.5. Business Strategy
10.4. GlaxoSmithKline plc, Inc
10.4.1. Overview
10.4.2. Financials
10.4.3. Products & Services
10.4.4. Recent Developments
10.4.5. Business Strategy
10.5. Novartis AG
10.5.1. Overview
10.5.2. Financials
10.5.3. Products & Services
10.5.4. Recent Developments
10.5.5. Business Strategy
10.6. 3M Company
10.6.1. Overview
10.6.2. Financials
10.6.3. Products & Services
10.6.4. Recent Developments
10.6.5. Business Strategy
10.7. Becton, Dickinson and Company
10.7.1. Overview
10.7.2. Financials
10.7.3. Products & Services
10.7.4. Recent Developments
10.7.5. Business Strategy
10.8. Sanofi
10.8.1. Overview
10.8.2. Financials
10.8.3. Products & Services
10.8.4. Recent Developments
10.8.5. Business Strategy
10.9. Merck & Co., Inc
10.9.1. Overview
10.9.2. Financials
10.9.3. Products & Services
10.9.4. Recent Developments
10.9.5. Business Strategy
10.10. Antares Pharma, Inc
10.10.1. Overview
10.10.2. Financials
10.10.3. Products & Services
10.10.4. Recent Developments
10.10.5. Business Strategy
11. COMPANIES TO WATCH
11.1. AbbVie
11.1.1. Overview
11.1.2. Products & Services
11.1.3. Business Strategy
11.2. Amgen
11.2.1. Overview
11.2.2. Products & Services
11.2.3. Business Strategy
11.3. Johnson & Johnson, Inc
11.3.1. Overview
11.3.2. Products & Services
11.3.3. Business Strategy
11.4. AstraZeneca
11.4.1. Overview
11.4.2. Products & Services
11.4.3. Business Strategy
11.5. Eli Lilly and Company
11.5.1. Overview
11.5.2. Products & Services
11.5.3. Business Strategy
11.6. Gilead Sciences, Inc
11.6.1. Overview
11.6.2. Products & Services
11.6.3. Business Strategy
11.7. Teva Pharmaceuticals
11.7.1. Overview
11.7.2. Products & Services
11.7.3. Business Strategy
11.8. Boehringer Ingelheim
11.8.1. Overview
11.8.2. Products & Services
11.8.3. Business Strategy
11.9. Bristol-Myers Squibb
11.9.1. Overview
11.9.2. Products & Services
11.9.3. Business Strategy
11.10. Genmab A/S
11.10.1. Overview
11.10.2. Products & Services
11.10.3. Business Strategy
12. ANALYST OPINION
13. ANNEXURE
13.1. Report Scope
13.2. Market Definitions
13.3. Research Methodology
13.3.1. Data Collation and In-house Estimation
13.3.2. Market Triangulation
13.3.3. Forecasting
13.4. Report Assumptions
13.5. Declarations
13.6. Stakeholders
13.7. Abbreviations
LIST OF TABLES
TABLE 1. GLOBAL PHARMACEUTICAL DRUG DELIVERY SYSTEM MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2020-2026 (USD BILLION)
TABLE 2. GLOBAL PHARMACEUTICAL DRUG DELIVERY SYSTEM MARKET VALUE FOR ORAL DRUG DELIVERY, BY GEOGRAPHY, 2020-2026 (USD BILLION)
TABLE 3. GLOBAL PHARMACEUTICAL DRUG DELIVERY SYSTEM MARKET VALUE FOR PULMONARY DRUG DELIVERY, BY GEOGRAPHY, 2020-2026 (USD BILLION)
TABLE 4. GLOBAL PHARMACEUTICAL DRUG DELIVERY SYSTEM MARKET VALUE FOR INJECTABLE DRUG DELIVERY, BY GEOGRAPHY, 2020-2026 (USD BILLION)
TABLE 5. GLOBAL PHARMACEUTICAL DRUG DELIVERY SYSTEM MARKET VALUE FOR OCULAR DRUG DELIVERY, BY GEOGRAPHY, 2020-2026 (USD BILLION)
TABLE 6. GLOBAL PHARMACEUTICAL DRUG DELIVERY SYSTEM MARKET VALUE FOR NASAL DRUG DELIVERY, BY GEOGRAPHY, 2020-2026 (USD BILLION)
TABLE 7. GLOBAL PHARMACEUTICAL DRUG DELIVERY SYSTEM MARKET VALUE FOR TOPICAL DRUG DELIVERY, BY GEOGRAPHY, 2020-2026 (USD BILLION)
TABLE 8. GLOBAL PHARMACEUTICAL DRUG DELIVERY SYSTEM MARKET VALUE FOR IMPLANTABLE DRUG DELIVERY, BY GEOGRAPHY, 2020-2026 (USD BILLION)
TABLE 9. GLOBAL PHARMACEUTICAL DRUG DELIVERY SYSTEM MARKET VALUE FOR TRANSMUCOSAL DRUG DELIVERY, BY GEOGRAPHY, 2020-2026 (USD BILLION)
TABLE 10. GLOBAL PHARMACEUTICAL DRUG DELIVERY SYSTEM MARKET VALUE, BY APPLICATION, 2020-2026 (USD BILLION)
TABLE 11. GLOBAL PHARMACEUTICAL DRUG DELIVERY SYSTEM MARKET VALUE FOR INFECTIOUS DISEASES, BY GEOGRAPHY, 2020-2026 (USD BILLION)
TABLE 12. GLOBAL PHARMACEUTICAL DRUG DELIVERY SYSTEM MARKET VALUE FOR CANCER, BY GEOGRAPHY, 2020-2026 (USD BILLION)
TABLE 13. GLOBAL PHARMACEUTICAL DRUG DELIVERY SYSTEM MARKET VALUE FOR CARDIOVASCULAR DISEASES, BY GEOGRAPHY, 2020-2026 (USD BILLION)
TABLE 14. GLOBAL PHARMACEUTICAL DRUG DELIVERY SYSTEM MARKET VALUE FOR DIABETES, BY GEOGRAPHY, 2020-2026 (USD BILLION)
TABLE 15. GLOBAL PHARMACEUTICAL DRUG DELIVERY SYSTEM MARKET VALUE FOR RESPIRATORY DISEASES, BY GEOGRAPHY, 2020-2026 (USD BILLION)
TABLE 16. GLOBAL PHARMACEUTICAL DRUG DELIVERY SYSTEM MARKET VALUE FOR CENTRAL NERVOUS SYSTEM DISORDERS, BY GEOGRAPHY, 2020-2026 (USD BILLION)
TABLE 17. GLOBAL PHARMACEUTICAL DRUG DELIVERY SYSTEM MARKET VALUE FOR AUTOIMMUNE DISEASES, BY GEOGRAPHY, 2020-2026 (USD BILLION)
TABLE 18. GLOBAL PHARMACEUTICAL DRUG DELIVERY SYSTEM MARKET VALUE, BY END-USER, 2020-2026 (USD BILLION)
TABLE 19. GLOBAL PHARMACEUTICAL DRUG DELIVERY SYSTEM MARKET VALUE FOR HOSPITALS, 2020-2026 (USD BILLION)
TABLE 20. GLOBAL PHARMACEUTICAL DRUG DELIVERY SYSTEMMARKET VALUE FOR HOME CARE SETTINGS, BY GEOGRAPHY, 2020-2026 (USD BILLION)
TABLE 21. GLOBAL PHARMACEUTICAL DRUG DELIVERY SYSTEM MARKET VALUE FOR AMBULATORY SURVEY CENTERS, BY GEOGRAPHY, 2020-2026 (USD BILLION)
TABLE 22. GLOBAL PHARMACEUTICAL DRUG DELIVERY SYSTEM MARKET VALUE FOR DIAGNOSTIC CENTERS, BY GEOGRAPHY, 2020-2026 (USD BILLION)
TABLE 23. NORTH AMERICA PHARMACEUTICAL DRUG DELIVERY SYSTEM MARKET VALUE, BY COUNTRY, 2020-2026 (USD BILLION)
TABLE 24. NORTH AMERICA PHARMACEUTICAL DRUG DELIVERY SYSTEM MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2020-2026 (USD BILLION)
TABLE 25. NORTH AMERICA PHARMACEUTICAL DRUG DELIVERY SYSTEM MARKET VALUE, BY APPLICATION, 2020-2026 (USD BILLION)
TABLE 26. NORTH AMERICA PHARMACEUTICAL DRUG DELIVERY SYSTEM MARKET VALUE, BY END-USER, 2020-2026 (USD BILLION)
TABLE 27. U.S PHARMACEUTICAL DRUG DELIVERY SYSTEM MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2020-2026 (USD BILLION)
TABLE 28. U.S PHARMACEUTICAL DRUG DELIVERY SYSTEM MARKET VALUE, BY APPLICATION, 2020-2026 (USD BILLION)
TABLE 29. U.S PHARMACEUTICAL DRUG DELIVERY SYSTEM MARKET VALUE, BY END-USER, 2020-2026 (USD BILLION)
TABLE 30. CANADA PHARMACEUTICAL DRUG DELIVERY SYSTEM MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2020-2026 (USD BILLION)
TABLE 31. CANADA PHARMACEUTICAL DRUG DELIVERY SYSTEM MARKET VALUE, BY APPLICATION, 2020-2026 (USD BILLION)
TABLE 32. CANADA PHARMACEUTICAL DRUG DELIVERY SYSTEM MARKET VALUE, BY END-USER, 2020-2026 (USD BILLION)
TABLE 33. EUROPE PHARMACEUTICAL DRUG DELIVERY SYSTEM MARKET VALUE, BY COUNTRY, 2020-2026 (USD BILLION)
TABLE 34. EUROPE PHARMACEUTICAL DRUG DELIVERY SYSTEM MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2020-2026 (USD BILLION)
TABLE 35. EUROPE PHARMACEUTICAL DRUG DELIVERY SYSTEM MARKET VALUE, BY APPLICATION, 2020-2026 (USD BILLION)
TABLE 36. EUROPE PHARMACEUTICAL DRUG DELIVERY SYSTEM MARKET VALUE, END-USER, 2020-2026 (USD BILLION)
TABLE 37. GERMANY PHARMACEUTICAL DRUG DELIVERY SYSTEM MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2020-2026 (USD BILLION)
TABLE 38. GERMANY PHARMACEUTICAL DRUG DELIVERY SYSTEM MARKET VALUE, BY APPLICATION, 2020-2026 (USD BILLION)
TABLE 39. GERMANY PHARMACEUTICAL DRUG DELIVERY SYSTEM MARKET VALUE, BY END-USER, 2020-2026 (USD BILLION)
TABLE 40. U.K PHARMACEUTICAL DRUG DELIVERY SYSTEM MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2020-2026 (USD BILLION)
TABLE 41. U.K PHARMACEUTICAL DRUG DELIVERY SYSTEM MARKET VALUE, BY APPLICATION, 2020-2026 (USD BILLION)
TABLE 42. U.K PHARMACEUTICAL DRUG DELIVERY SYSTEM MARKET VALUE, BY END-USER, 2020-2026 (USD BILLION)
TABLE 43. FRANCE PHARMACEUTICAL DRUG DELIVERY SYSTEM MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2020-2026 (USD BILLION)
TABLE 44. FRANCE PHARMACEUTICAL DRUG DELIVERY SYSTEM MARKET VALUE, BY APPLICATION, 2020-2026 (USD BILLION)
TABLE 45. FRANCE PHARMACEUTICAL DRUG DELIVERY SYSTEM MARKET VALUE, BY END-USER, 2020-2026 (USD BILLION)
TABLE 46. ITALY PHARMACEUTICAL DRUG DELIVERY SYSTEM MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2020-2026 (USD BILLION)
TABLE 47. ITALY PHARMACEUTICAL DRUG DELIVERY SYSTEM MARKET VALUE, BY APPLICATION, 2020-2026 (USD BILLION)
TABLE 48. ITALY PHARMACEUTICAL DRUG DELIVERY SYSTEM MARKET VALUE, BY END-USER, 2020-2026 (USD BILLION)
TABLE 49. SPAIN PHARMACEUTICAL DRUG DELIVERY SYSTEM MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2020-2026 (USD BILLION)
TABLE 50. SPAIN PHARMACEUTICAL DRUG DELIVERY SYSTEM MARKET VALUE, BY APPLICATION, 2020-2026 (USD BILLION)
TABLE 51. SPAIN PHARMACEUTICAL DRUG DELIVERY SYSTEM MARKET VALUE, BY END-USER, 2020-2026 (USD BILLION)
TABLE 52. ROE PHARMACEUTICAL DRUG DELIVERY SYSTEM MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2020-2026 (USD BILLION)
TABLE 53. ROE PHARMACEUTICAL DRUG DELIVERY SYSTEM MARKET VALUE, BY APPLICATION, 2020-2026 (USD BILLION)
TABLE 54. ROE PHARMACEUTICAL DRUG DELIVERY SYSTEM MARKET VALUE, BY END-USER, 2020-2026 (USD BILLION)
TABLE 55. ASIA PACIFC PHARMACEUTICAL DRUG DELIVERY SYSTEM MARKET VALUE, BY COUNTRY, 2020-2026 (USD BILLION)
TABLE 56. ASIA PACIFC PHARMACEUTICAL DRUG DELIVERY SYSTEM MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2020-2026 (USD BILLION)
TABLE 57. ASIA PACIFC PHARMACEUTICAL DRUG DELIVERY SYSTEM MARKET VALUE, BY APPLICATION, 2020-2026 (USD BILLION)
TABLE 58. ASIA PACIFC PHARMACEUTICAL DRUG DELIVERY SYSTEM MARKET VALUE, BY END-USER, 2020-2026 (USD BILLION)
TABLE 59. CHINA PHARMACEUTICAL DRUG DELIVERY SYSTEM MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2020-2026 (USD BILLION)
TABLE 60. CHINA PHARMACEUTICAL DRUG DELIVERY SYSTEM MARKET VALUE, BY APPLICATION, 2020-2026 (USD BILLION)
TABLE 61. CHINA PHARMACEUTICAL DRUG DELIVERY SYSTEM MARKET VALUE, BY END-USER, 2020-2026 (USD BILLION)
TABLE 62. INDIA PHARMACEUTICAL DRUG DELIVERY SYSTEM MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2020-2026 (USD BILLION)
TABLE 63. INDIA PHARMACEUTICAL DRUG DELIVERY SYSTEM MARKET VALUE, BY APPLICATION, 2020-2026 (USD BILLION)
TABLE 64. INDIA PHARMACEUTICAL DRUG DELIVERY SYSTEM MARKET VALUE, BY END-USER, 2020-2026 (USD BILLION)
TABLE 65. JAPAN PHARMACEUTICAL DRUG DELIVERY SYSTEM MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2020-2026 (USD BILLION)
TABLE 66. JAPAN PHARMACEUTICAL DRUG DELIVERY SYSTEM MARKET VALUE, BY APPLICATION, 2020-2026 (USD BILLION)
TABLE 67. JAPAN PHARMACEUTICAL DRUG DELIVERY SYSTEM MARKET VALUE, BY END-USER, 2020-2026 (USD BILLION)
TABLE 68. REST OF APAC PHARMACEUTICAL DRUG DELIVERY SYSTEM MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2020-2026 (USD BILLION)
TABLE 69. REST OF APAC PHARMACEUTICAL DRUG DELIVERY SYSTEM MARKET VALUE, BY APPLICATION, 2020-2026 (USD BILLION)
TABLE 70. REST OF APAC PHARMACEUTICAL DRUG DELIVERY SYSTEM MARKET VALUE, BY END-USER, 2020-2026 (USD BILLION)
TABLE 71. REST OF WORLD PHARMACEUTICAL DRUG DELIVERY SYSTEM MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2020-2026 (USD BILLION)
TABLE 72. REST OF WORLD PHARMACEUTICAL DRUG DELIVERY SYSTEM MARKET VALUE, BY APPLICATION, 2020-2026 (USD BILLION)
TABLE 73. REST OF WORLD PHARMACEUTICAL DRUG DELIVERY SYSTEM MARKET VALUE, BY END-USER, 2020-2026 (USD BILLION)
TABLE 74. F. HOFFMAN-LA ROCHE: FINANCIALS
TABLE 75. F. HOFFMAN-LA ROCHE: PRODUCTS & SERVICES
TABLE 76. F. HOFFMAN-LA ROCHE: RECENT DEVELOPMENTS
TABLE 77. BAYER AG: FINANCIALS
TABLE 78. BAYER AG: PRODUCTS & SERVICES
TABLE 79. BAYER AG: RECENT DEVELOPMENTS
TABLE 80. PFIZER: FINANCIALS
TABLE 81. PFIZER: PRODUCTS & SERVICES
TABLE 82. PFIZER: RECENT DEVELOPMENTS
TABLE 83. GLAXOSMITHKLINE PLC, INC: FINANCIALS
TABLE 84. GLAXOSMITHKLINE PLC, INC: PRODUCTS & SERVICES
TABLE 85. GLAXOSMITHKLINE PLC, INC: RECENT DEVELOPMENTS
TABLE 86. NOVARTIS AG: FINANCIALS
TABLE 87. NOVARTIS AG: PRODUCTS & SERVICES
TABLE 88. NOVARTIS AG: RECENT DEVELOPMENTS
TABLE 89. 3M COMPANY: FINANCIALS
TABLE 90. 3M COMPANY: PRODUCTS & SERVICES
TABLE 91. 3M COMPANY: RECENT DEVELOPMENTS
TABLE 92. BECTON, DICKINSON AND COMPANY: FINANCIALS
TABLE 93. BECTON, DICKINSON AND COMPANY: PRODUCTS & SERVICES
TABLE 94. BECTON, DICKINSON AND COMPANY: RECENT DEVELOPMENTS
TABLE 95. SANOFI: FINANCIALS
TABLE 96. SANOFI: PRODUCTS & SERVICES
TABLE 97. SANOFI: RECENT DEVELOPMENTS
TABLE 98. MERCK & CO., INC.: FINANCIALS
TABLE 99. MERCK & CO., INC.: PRODUCTS & SERVICES
TABLE 100. MERCK & CO., INC.: RECENT DEVELOPMENTS
TABLE 101. ANTARES PHARMA, INC.: FINANCIALS
TABLE 102. ANTARES PHARMA, INC.: PRODUCTS & SERVICES
TABLE 103. ANTARES PHARMA, INC.: RECENT DEVELOPMENTS
TABLE 104. ABBVIE: PRODUCTS & SERVICES
TABLE 105. AMGEN: PRODUCTS & SERVICES
TABLE 106. JOHNSON & JOHNSON, INC: PRODUCTS & SERVICES
TABLE 107. ASTRAZENECA: PRODUCTS & SERVICES
TABLE 108. ELI LILLY AND COMPANY: PRODUCTS & SERVICES
TABLE 109. GILEAD SCIENCES, INC.: PRODUCTS & SERVICES
TABLE 110. TEVA PHARMACEUTICALS: PRODUCTS & SERVICES
TABLE 111. BOEHRINGER INGELHEIM: PRODUCTS & SERVICES
TABLE 112. BRISTOL-MYERS SQUIBB: PRODUCTS & SERVICES
TABLE 113. GENMAB A/S: PRODUCTS & SERVICES
TABLE 1. GLOBAL PHARMACEUTICAL DRUG DELIVERY SYSTEM MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2020-2026 (USD BILLION)
TABLE 2. GLOBAL PHARMACEUTICAL DRUG DELIVERY SYSTEM MARKET VALUE FOR ORAL DRUG DELIVERY, BY GEOGRAPHY, 2020-2026 (USD BILLION)
TABLE 3. GLOBAL PHARMACEUTICAL DRUG DELIVERY SYSTEM MARKET VALUE FOR PULMONARY DRUG DELIVERY, BY GEOGRAPHY, 2020-2026 (USD BILLION)
TABLE 4. GLOBAL PHARMACEUTICAL DRUG DELIVERY SYSTEM MARKET VALUE FOR INJECTABLE DRUG DELIVERY, BY GEOGRAPHY, 2020-2026 (USD BILLION)
TABLE 5. GLOBAL PHARMACEUTICAL DRUG DELIVERY SYSTEM MARKET VALUE FOR OCULAR DRUG DELIVERY, BY GEOGRAPHY, 2020-2026 (USD BILLION)
TABLE 6. GLOBAL PHARMACEUTICAL DRUG DELIVERY SYSTEM MARKET VALUE FOR NASAL DRUG DELIVERY, BY GEOGRAPHY, 2020-2026 (USD BILLION)
TABLE 7. GLOBAL PHARMACEUTICAL DRUG DELIVERY SYSTEM MARKET VALUE FOR TOPICAL DRUG DELIVERY, BY GEOGRAPHY, 2020-2026 (USD BILLION)
TABLE 8. GLOBAL PHARMACEUTICAL DRUG DELIVERY SYSTEM MARKET VALUE FOR IMPLANTABLE DRUG DELIVERY, BY GEOGRAPHY, 2020-2026 (USD BILLION)
TABLE 9. GLOBAL PHARMACEUTICAL DRUG DELIVERY SYSTEM MARKET VALUE FOR TRANSMUCOSAL DRUG DELIVERY, BY GEOGRAPHY, 2020-2026 (USD BILLION)
TABLE 10. GLOBAL PHARMACEUTICAL DRUG DELIVERY SYSTEM MARKET VALUE, BY APPLICATION, 2020-2026 (USD BILLION)
TABLE 11. GLOBAL PHARMACEUTICAL DRUG DELIVERY SYSTEM MARKET VALUE FOR INFECTIOUS DISEASES, BY GEOGRAPHY, 2020-2026 (USD BILLION)
TABLE 12. GLOBAL PHARMACEUTICAL DRUG DELIVERY SYSTEM MARKET VALUE FOR CANCER, BY GEOGRAPHY, 2020-2026 (USD BILLION)
TABLE 13. GLOBAL PHARMACEUTICAL DRUG DELIVERY SYSTEM MARKET VALUE FOR CARDIOVASCULAR DISEASES, BY GEOGRAPHY, 2020-2026 (USD BILLION)
TABLE 14. GLOBAL PHARMACEUTICAL DRUG DELIVERY SYSTEM MARKET VALUE FOR DIABETES, BY GEOGRAPHY, 2020-2026 (USD BILLION)
TABLE 15. GLOBAL PHARMACEUTICAL DRUG DELIVERY SYSTEM MARKET VALUE FOR RESPIRATORY DISEASES, BY GEOGRAPHY, 2020-2026 (USD BILLION)
TABLE 16. GLOBAL PHARMACEUTICAL DRUG DELIVERY SYSTEM MARKET VALUE FOR CENTRAL NERVOUS SYSTEM DISORDERS, BY GEOGRAPHY, 2020-2026 (USD BILLION)
TABLE 17. GLOBAL PHARMACEUTICAL DRUG DELIVERY SYSTEM MARKET VALUE FOR AUTOIMMUNE DISEASES, BY GEOGRAPHY, 2020-2026 (USD BILLION)
TABLE 18. GLOBAL PHARMACEUTICAL DRUG DELIVERY SYSTEM MARKET VALUE, BY END-USER, 2020-2026 (USD BILLION)
TABLE 19. GLOBAL PHARMACEUTICAL DRUG DELIVERY SYSTEM MARKET VALUE FOR HOSPITALS, 2020-2026 (USD BILLION)
TABLE 20. GLOBAL PHARMACEUTICAL DRUG DELIVERY SYSTEMMARKET VALUE FOR HOME CARE SETTINGS, BY GEOGRAPHY, 2020-2026 (USD BILLION)
TABLE 21. GLOBAL PHARMACEUTICAL DRUG DELIVERY SYSTEM MARKET VALUE FOR AMBULATORY SURVEY CENTERS, BY GEOGRAPHY, 2020-2026 (USD BILLION)
TABLE 22. GLOBAL PHARMACEUTICAL DRUG DELIVERY SYSTEM MARKET VALUE FOR DIAGNOSTIC CENTERS, BY GEOGRAPHY, 2020-2026 (USD BILLION)
TABLE 23. NORTH AMERICA PHARMACEUTICAL DRUG DELIVERY SYSTEM MARKET VALUE, BY COUNTRY, 2020-2026 (USD BILLION)
TABLE 24. NORTH AMERICA PHARMACEUTICAL DRUG DELIVERY SYSTEM MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2020-2026 (USD BILLION)
TABLE 25. NORTH AMERICA PHARMACEUTICAL DRUG DELIVERY SYSTEM MARKET VALUE, BY APPLICATION, 2020-2026 (USD BILLION)
TABLE 26. NORTH AMERICA PHARMACEUTICAL DRUG DELIVERY SYSTEM MARKET VALUE, BY END-USER, 2020-2026 (USD BILLION)
TABLE 27. U.S PHARMACEUTICAL DRUG DELIVERY SYSTEM MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2020-2026 (USD BILLION)
TABLE 28. U.S PHARMACEUTICAL DRUG DELIVERY SYSTEM MARKET VALUE, BY APPLICATION, 2020-2026 (USD BILLION)
TABLE 29. U.S PHARMACEUTICAL DRUG DELIVERY SYSTEM MARKET VALUE, BY END-USER, 2020-2026 (USD BILLION)
TABLE 30. CANADA PHARMACEUTICAL DRUG DELIVERY SYSTEM MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2020-2026 (USD BILLION)
TABLE 31. CANADA PHARMACEUTICAL DRUG DELIVERY SYSTEM MARKET VALUE, BY APPLICATION, 2020-2026 (USD BILLION)
TABLE 32. CANADA PHARMACEUTICAL DRUG DELIVERY SYSTEM MARKET VALUE, BY END-USER, 2020-2026 (USD BILLION)
TABLE 33. EUROPE PHARMACEUTICAL DRUG DELIVERY SYSTEM MARKET VALUE, BY COUNTRY, 2020-2026 (USD BILLION)
TABLE 34. EUROPE PHARMACEUTICAL DRUG DELIVERY SYSTEM MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2020-2026 (USD BILLION)
TABLE 35. EUROPE PHARMACEUTICAL DRUG DELIVERY SYSTEM MARKET VALUE, BY APPLICATION, 2020-2026 (USD BILLION)
TABLE 36. EUROPE PHARMACEUTICAL DRUG DELIVERY SYSTEM MARKET VALUE, END-USER, 2020-2026 (USD BILLION)
TABLE 37. GERMANY PHARMACEUTICAL DRUG DELIVERY SYSTEM MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2020-2026 (USD BILLION)
TABLE 38. GERMANY PHARMACEUTICAL DRUG DELIVERY SYSTEM MARKET VALUE, BY APPLICATION, 2020-2026 (USD BILLION)
TABLE 39. GERMANY PHARMACEUTICAL DRUG DELIVERY SYSTEM MARKET VALUE, BY END-USER, 2020-2026 (USD BILLION)
TABLE 40. U.K PHARMACEUTICAL DRUG DELIVERY SYSTEM MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2020-2026 (USD BILLION)
TABLE 41. U.K PHARMACEUTICAL DRUG DELIVERY SYSTEM MARKET VALUE, BY APPLICATION, 2020-2026 (USD BILLION)
TABLE 42. U.K PHARMACEUTICAL DRUG DELIVERY SYSTEM MARKET VALUE, BY END-USER, 2020-2026 (USD BILLION)
TABLE 43. FRANCE PHARMACEUTICAL DRUG DELIVERY SYSTEM MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2020-2026 (USD BILLION)
TABLE 44. FRANCE PHARMACEUTICAL DRUG DELIVERY SYSTEM MARKET VALUE, BY APPLICATION, 2020-2026 (USD BILLION)
TABLE 45. FRANCE PHARMACEUTICAL DRUG DELIVERY SYSTEM MARKET VALUE, BY END-USER, 2020-2026 (USD BILLION)
TABLE 46. ITALY PHARMACEUTICAL DRUG DELIVERY SYSTEM MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2020-2026 (USD BILLION)
TABLE 47. ITALY PHARMACEUTICAL DRUG DELIVERY SYSTEM MARKET VALUE, BY APPLICATION, 2020-2026 (USD BILLION)
TABLE 48. ITALY PHARMACEUTICAL DRUG DELIVERY SYSTEM MARKET VALUE, BY END-USER, 2020-2026 (USD BILLION)
TABLE 49. SPAIN PHARMACEUTICAL DRUG DELIVERY SYSTEM MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2020-2026 (USD BILLION)
TABLE 50. SPAIN PHARMACEUTICAL DRUG DELIVERY SYSTEM MARKET VALUE, BY APPLICATION, 2020-2026 (USD BILLION)
TABLE 51. SPAIN PHARMACEUTICAL DRUG DELIVERY SYSTEM MARKET VALUE, BY END-USER, 2020-2026 (USD BILLION)
TABLE 52. ROE PHARMACEUTICAL DRUG DELIVERY SYSTEM MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2020-2026 (USD BILLION)
TABLE 53. ROE PHARMACEUTICAL DRUG DELIVERY SYSTEM MARKET VALUE, BY APPLICATION, 2020-2026 (USD BILLION)
TABLE 54. ROE PHARMACEUTICAL DRUG DELIVERY SYSTEM MARKET VALUE, BY END-USER, 2020-2026 (USD BILLION)
TABLE 55. ASIA PACIFC PHARMACEUTICAL DRUG DELIVERY SYSTEM MARKET VALUE, BY COUNTRY, 2020-2026 (USD BILLION)
TABLE 56. ASIA PACIFC PHARMACEUTICAL DRUG DELIVERY SYSTEM MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2020-2026 (USD BILLION)
TABLE 57. ASIA PACIFC PHARMACEUTICAL DRUG DELIVERY SYSTEM MARKET VALUE, BY APPLICATION, 2020-2026 (USD BILLION)
TABLE 58. ASIA PACIFC PHARMACEUTICAL DRUG DELIVERY SYSTEM MARKET VALUE, BY END-USER, 2020-2026 (USD BILLION)
TABLE 59. CHINA PHARMACEUTICAL DRUG DELIVERY SYSTEM MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2020-2026 (USD BILLION)
TABLE 60. CHINA PHARMACEUTICAL DRUG DELIVERY SYSTEM MARKET VALUE, BY APPLICATION, 2020-2026 (USD BILLION)
TABLE 61. CHINA PHARMACEUTICAL DRUG DELIVERY SYSTEM MARKET VALUE, BY END-USER, 2020-2026 (USD BILLION)
TABLE 62. INDIA PHARMACEUTICAL DRUG DELIVERY SYSTEM MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2020-2026 (USD BILLION)
TABLE 63. INDIA PHARMACEUTICAL DRUG DELIVERY SYSTEM MARKET VALUE, BY APPLICATION, 2020-2026 (USD BILLION)
TABLE 64. INDIA PHARMACEUTICAL DRUG DELIVERY SYSTEM MARKET VALUE, BY END-USER, 2020-2026 (USD BILLION)
TABLE 65. JAPAN PHARMACEUTICAL DRUG DELIVERY SYSTEM MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2020-2026 (USD BILLION)
TABLE 66. JAPAN PHARMACEUTICAL DRUG DELIVERY SYSTEM MARKET VALUE, BY APPLICATION, 2020-2026 (USD BILLION)
TABLE 67. JAPAN PHARMACEUTICAL DRUG DELIVERY SYSTEM MARKET VALUE, BY END-USER, 2020-2026 (USD BILLION)
TABLE 68. REST OF APAC PHARMACEUTICAL DRUG DELIVERY SYSTEM MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2020-2026 (USD BILLION)
TABLE 69. REST OF APAC PHARMACEUTICAL DRUG DELIVERY SYSTEM MARKET VALUE, BY APPLICATION, 2020-2026 (USD BILLION)
TABLE 70. REST OF APAC PHARMACEUTICAL DRUG DELIVERY SYSTEM MARKET VALUE, BY END-USER, 2020-2026 (USD BILLION)
TABLE 71. REST OF WORLD PHARMACEUTICAL DRUG DELIVERY SYSTEM MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2020-2026 (USD BILLION)
TABLE 72. REST OF WORLD PHARMACEUTICAL DRUG DELIVERY SYSTEM MARKET VALUE, BY APPLICATION, 2020-2026 (USD BILLION)
TABLE 73. REST OF WORLD PHARMACEUTICAL DRUG DELIVERY SYSTEM MARKET VALUE, BY END-USER, 2020-2026 (USD BILLION)
TABLE 74. F. HOFFMAN-LA ROCHE: FINANCIALS
TABLE 75. F. HOFFMAN-LA ROCHE: PRODUCTS & SERVICES
TABLE 76. F. HOFFMAN-LA ROCHE: RECENT DEVELOPMENTS
TABLE 77. BAYER AG: FINANCIALS
TABLE 78. BAYER AG: PRODUCTS & SERVICES
TABLE 79. BAYER AG: RECENT DEVELOPMENTS
TABLE 80. PFIZER: FINANCIALS
TABLE 81. PFIZER: PRODUCTS & SERVICES
TABLE 82. PFIZER: RECENT DEVELOPMENTS
TABLE 83. GLAXOSMITHKLINE PLC, INC: FINANCIALS
TABLE 84. GLAXOSMITHKLINE PLC, INC: PRODUCTS & SERVICES
TABLE 85. GLAXOSMITHKLINE PLC, INC: RECENT DEVELOPMENTS
TABLE 86. NOVARTIS AG: FINANCIALS
TABLE 87. NOVARTIS AG: PRODUCTS & SERVICES
TABLE 88. NOVARTIS AG: RECENT DEVELOPMENTS
TABLE 89. 3M COMPANY: FINANCIALS
TABLE 90. 3M COMPANY: PRODUCTS & SERVICES
TABLE 91. 3M COMPANY: RECENT DEVELOPMENTS
TABLE 92. BECTON, DICKINSON AND COMPANY: FINANCIALS
TABLE 93. BECTON, DICKINSON AND COMPANY: PRODUCTS & SERVICES
TABLE 94. BECTON, DICKINSON AND COMPANY: RECENT DEVELOPMENTS
TABLE 95. SANOFI: FINANCIALS
TABLE 96. SANOFI: PRODUCTS & SERVICES
TABLE 97. SANOFI: RECENT DEVELOPMENTS
TABLE 98. MERCK & CO., INC.: FINANCIALS
TABLE 99. MERCK & CO., INC.: PRODUCTS & SERVICES
TABLE 100. MERCK & CO., INC.: RECENT DEVELOPMENTS
TABLE 101. ANTARES PHARMA, INC.: FINANCIALS
TABLE 102. ANTARES PHARMA, INC.: PRODUCTS & SERVICES
TABLE 103. ANTARES PHARMA, INC.: RECENT DEVELOPMENTS
TABLE 104. ABBVIE: PRODUCTS & SERVICES
TABLE 105. AMGEN: PRODUCTS & SERVICES
TABLE 106. JOHNSON & JOHNSON, INC: PRODUCTS & SERVICES
TABLE 107. ASTRAZENECA: PRODUCTS & SERVICES
TABLE 108. ELI LILLY AND COMPANY: PRODUCTS & SERVICES
TABLE 109. GILEAD SCIENCES, INC.: PRODUCTS & SERVICES
TABLE 110. TEVA PHARMACEUTICALS: PRODUCTS & SERVICES
TABLE 111. BOEHRINGER INGELHEIM: PRODUCTS & SERVICES
TABLE 112. BRISTOL-MYERS SQUIBB: PRODUCTS & SERVICES
TABLE 113. GENMAB A/S: PRODUCTS & SERVICES
LIST OF FIGURES
CHART. 1. GLOBAL PHARMACEUTICAL DRUG DELIVERY SYSTEM MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2020-2026 (USD BILLION)
CHART. 2. GLOBAL PHARMACEUTICAL DRUG DELIVERY SYSTEM MARKET VALUE FOR ORAL DRUG DELIVERY, BY GEOGRAPHY, 2020-2026 (USD BILLION)
CHART. 3. GLOBAL PHARMACEUTICAL DRUG DELIVERY SYSTEM MARKET VALUE FOR PULMONARY DRUG DELIVERY, BY GEOGRAPHY, 2020-2026 (USD BILLION)
CHART. 4. GLOBAL PHARMACEUTICAL DRUG DELIVERY SYSTEM MARKET VALUE FOR INJECTABLE DRUG DELIVERY, BY GEOGRAPHY, 2020-2026 (USD BILLION)
CHART. 5. GLOBAL PHARMACEUTICAL DRUG DELIVERY SYSTEM MARKET VALUE FOR OCULAR DRUG DELIVERY, BY GEOGRAPHY, 2020-2026 (USD BILLION)
CHART. 6. GLOBAL PHARMACEUTICAL DRUG DELIVERY SYSTEM MARKET VALUE FOR NASAL DRUG DELIVERY, BY GEOGRAPHY, 2020-2026 (USD BILLION)
CHART. 7. GLOBAL PHARMACEUTICAL DRUG DELIVERY SYSTEM MARKET VALUE FOR TOPICAL DRUG DELIVERY, BY GEOGRAPHY, 2020-2026 (USD BILLION)
CHART. 8. GLOBAL PHARMACEUTICAL DRUG DELIVERY SYSTEM MARKET VALUE FOR IMPLANTABLE DRUG DELIVERY, BY GEOGRAPHY, 2020-2026 (USD BILLION)
CHART. 9. GLOBAL PHARMACEUTICAL DRUG DELIVERY SYSTEM MARKET VALUE FOR TRANSMUCOSAL DRUG DELIVERY, BY GEOGRAPHY, 2020-2026 (USD BILLION)
CHART. 10. GLOBAL PHARMACEUTICAL DRUG DELIVERY SYSTEM MARKET VALUE, BY APPLICATION, 2020-2026 (USD BILLION)
CHART. 11. GLOBAL PHARMACEUTICAL DRUG DELIVERY SYSTEM MARKET VALUE FOR INFECTIOUS DISEASES, BY GEOGRAPHY, 2020-2026 (USD BILLION)
CHART. 12. GLOBAL PHARMACEUTICAL DRUG DELIVERY SYSTEM MARKET VALUE FOR CANCER, BY GEOGRAPHY, 2020-2026 (USD BILLION)
CHART. 13. GLOBAL PHARMACEUTICAL DRUG DELIVERY SYSTEM MARKET VALUE FOR CARDIOVASCULAR DISEASES, BY GEOGRAPHY, 2020-2026 (USD BILLION)
CHART. 14. GLOBAL PHARMACEUTICAL DRUG DELIVERY SYSTEM MARKET VALUE FOR DIABETES, BY GEOGRAPHY, 2020-2026 (USD BILLION)
CHART. 15. GLOBAL PHARMACEUTICAL DRUG DELIVERY SYSTEM MARKET VALUE FOR RESPIRATORY DISEASES, BY GEOGRAPHY, 2020-2026 (USD BILLION)
CHART. 16. GLOBAL PHARMACEUTICAL DRUG DELIVERY SYSTEM MARKET VALUE FOR CENTRAL NERVOUS SYSTEM DISORDERS, BY GEOGRAPHY, 2020-2026 (USD BILLION)
CHART. 17. GLOBAL PHARMACEUTICAL DRUG DELIVERY SYSTEM MARKET VALUE FOR AUTOIMMUNE DISEASES, BY GEOGRAPHY, 2020-2026 (USD BILLION)
CHART. 18. GLOBAL PHARMACEUTICAL DRUG DELIVERY SYSTEM MARKET VALUE, BY END-USER, 2020-2026 (USD BILLION)
CHART. 19. GLOBAL PHARMACEUTICAL DRUG DELIVERY SYSTEM MARKET VALUE FOR HOSPITALS, 2020-2026 (USD BILLION)
CHART. 20. GLOBAL PHARMACEUTICAL DRUG DELIVERY SYSTEMMARKET VALUE FOR HOME CARE SETTINGS, BY GEOGRAPHY, 2020-2026 (USD BILLION)
CHART. 21. GLOBAL PHARMACEUTICAL DRUG DELIVERY SYSTEM MARKET VALUE FOR AMBULATORY SURVEY CENTERS, BY GEOGRAPHY, 2020-2026 (USD BILLION)
CHART. 22. GLOBAL PHARMACEUTICAL DRUG DELIVERY SYSTEM MARKET VALUE FOR DIAGNOSTIC CENTERS, BY GEOGRAPHY, 2020-2026 (USD BILLION)
CHART. 23. NORTH AMERICA PHARMACEUTICAL DRUG DELIVERY SYSTEM MARKET VALUE, BY COUNTRY, 2020-2026 (USD BILLION)
CHART. 24. NORTH AMERICA PHARMACEUTICAL DRUG DELIVERY SYSTEM MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2020-2026 (USD BILLION)
CHART. 25. NORTH AMERICA PHARMACEUTICAL DRUG DELIVERY SYSTEM MARKET VALUE, BY APPLICATION, 2020-2026 (USD BILLION)
CHART. 26. NORTH AMERICA PHARMACEUTICAL DRUG DELIVERY SYSTEM MARKET VALUE, BY END-USER, 2020-2026 (USD BILLION)
CHART. 27. U.S PHARMACEUTICAL DRUG DELIVERY SYSTEM MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2020-2026 (USD BILLION)
CHART. 28. U.S PHARMACEUTICAL DRUG DELIVERY SYSTEM MARKET VALUE, BY APPLICATION, 2020-2026 (USD BILLION)
CHART. 29. U.S PHARMACEUTICAL DRUG DELIVERY SYSTEM MARKET VALUE, BY END-USER, 2020-2026 (USD BILLION)
CHART. 30. CANADA PHARMACEUTICAL DRUG DELIVERY SYSTEM MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2020-2026 (USD BILLION)
CHART. 31. CANADA PHARMACEUTICAL DRUG DELIVERY SYSTEM MARKET VALUE, BY APPLICATION, 2020-2026 (USD BILLION)
CHART. 32. CANADA PHARMACEUTICAL DRUG DELIVERY SYSTEM MARKET VALUE, BY END-USER, 2020-2026 (USD BILLION)
CHART. 33. EUROPE PHARMACEUTICAL DRUG DELIVERY SYSTEM MARKET VALUE, BY COUNTRY, 2020-2026 (USD BILLION)
CHART. 34. EUROPE PHARMACEUTICAL DRUG DELIVERY SYSTEM MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2020-2026 (USD BILLION)
CHART. 35. EUROPE PHARMACEUTICAL DRUG DELIVERY SYSTEM MARKET VALUE, BY APPLICATION, 2020-2026 (USD BILLION)
CHART. 36. EUROPE PHARMACEUTICAL DRUG DELIVERY SYSTEM MARKET VALUE, END-USER, 2020-2026 (USD BILLION)
CHART. 37. GERMANY PHARMACEUTICAL DRUG DELIVERY SYSTEM MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2020-2026 (USD BILLION)
CHART. 38. GERMANY PHARMACEUTICAL DRUG DELIVERY SYSTEM MARKET VALUE, BY APPLICATION, 2020-2026 (USD BILLION)
CHART. 39. GERMANY PHARMACEUTICAL DRUG DELIVERY SYSTEM MARKET VALUE, BY END-USER, 2020-2026 (USD BILLION)
CHART. 40. U.K PHARMACEUTICAL DRUG DELIVERY SYSTEM MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2020-2026 (USD BILLION)
CHART. 41. U.K PHARMACEUTICAL DRUG DELIVERY SYSTEM MARKET VALUE, BY APPLICATION, 2020-2026 (USD BILLION)
CHART. 42. U.K PHARMACEUTICAL DRUG DELIVERY SYSTEM MARKET VALUE, BY END-USER, 2020-2026 (USD BILLION)
CHART. 43. FRANCE PHARMACEUTICAL DRUG DELIVERY SYSTEM MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2020-2026 (USD BILLION)
CHART. 44. FRANCE PHARMACEUTICAL DRUG DELIVERY SYSTEM MARKET VALUE, BY APPLICATION, 2020-2026 (USD BILLION)
CHART. 45. FRANCE PHARMACEUTICAL DRUG DELIVERY SYSTEM MARKET VALUE, BY END-USER, 2020-2026 (USD BILLION)
CHART. 46. ITALY PHARMACEUTICAL DRUG DELIVERY SYSTEM MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2020-2026 (USD BILLION)
CHART. 47. ITALY PHARMACEUTICAL DRUG DELIVERY SYSTEM MARKET VALUE, BY APPLICATION, 2020-2026 (USD BILLION)
CHART. 48. ITALY PHARMACEUTICAL DRUG DELIVERY SYSTEM MARKET VALUE, BY END-USER, 2020-2026 (USD BILLION)
CHART. 49. SPAIN PHARMACEUTICAL DRUG DELIVERY SYSTEM MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2020-2026 (USD BILLION)
CHART. 50. SPAIN PHARMACEUTICAL DRUG DELIVERY SYSTEM MARKET VALUE, BY APPLICATION, 2020-2026 (USD BILLION)
CHART. 51. SPAIN PHARMACEUTICAL DRUG DELIVERY SYSTEM MARKET VALUE, BY END-USER, 2020-2026 (USD BILLION)
CHART. 52. ROE PHARMACEUTICAL DRUG DELIVERY SYSTEM MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2020-2026 (USD BILLION)
CHART. 53. ROE PHARMACEUTICAL DRUG DELIVERY SYSTEM MARKET VALUE, BY APPLICATION, 2020-2026 (USD BILLION)
CHART. 54. ROE PHARMACEUTICAL DRUG DELIVERY SYSTEM MARKET VALUE, BY END-USER, 2020-2026 (USD BILLION)
CHART. 55. ASIA PACIFC PHARMACEUTICAL DRUG DELIVERY SYSTEM MARKET VALUE, BY COUNTRY, 2020-2026 (USD BILLION)
CHART. 56. ASIA PACIFC PHARMACEUTICAL DRUG DELIVERY SYSTEM MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2020-2026 (USD BILLION)
CHART. 57. ASIA PACIFC PHARMACEUTICAL DRUG DELIVERY SYSTEM MARKET VALUE, BY APPLICATION, 2020-2026 (USD BILLION)
CHART. 58. ASIA PACIFC PHARMACEUTICAL DRUG DELIVERY SYSTEM MARKET VALUE, BY END-USER, 2020-2026 (USD BILLION)
CHART. 59. CHINA PHARMACEUTICAL DRUG DELIVERY SYSTEM MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2020-2026 (USD BILLION)
CHART. 60. CHINA PHARMACEUTICAL DRUG DELIVERY SYSTEM MARKET VALUE, BY APPLICATION, 2020-2026 (USD BILLION)
CHART. 61. CHINA PHARMACEUTICAL DRUG DELIVERY SYSTEM MARKET VALUE, BY END-USER, 2020-2026 (USD BILLION)
CHART. 62. INDIA PHARMACEUTICAL DRUG DELIVERY SYSTEM MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2020-2026 (USD BILLION)
CHART. 63. INDIA PHARMACEUTICAL DRUG DELIVERY SYSTEM MARKET VALUE, BY APPLICATION, 2020-2026 (USD BILLION)
CHART. 64. INDIA PHARMACEUTICAL DRUG DELIVERY SYSTEM MARKET VALUE, BY END-USER, 2020-2026 (USD BILLION)
CHART. 65. JAPAN PHARMACEUTICAL DRUG DELIVERY SYSTEM MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2020-2026 (USD BILLION)
CHART. 66. JAPAN PHARMACEUTICAL DRUG DELIVERY SYSTEM MARKET VALUE, BY APPLICATION, 2020-2026 (USD BILLION)
CHART. 67. JAPAN PHARMACEUTICAL DRUG DELIVERY SYSTEM MARKET VALUE, BY END-USER, 2020-2026 (USD BILLION)
CHART. 68. REST OF APAC PHARMACEUTICAL DRUG DELIVERY SYSTEM MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2020-2026 (USD BILLION)
CHART. 69. REST OF APAC PHARMACEUTICAL DRUG DELIVERY SYSTEM MARKET VALUE, BY APPLICATION, 2020-2026 (USD BILLION)
CHART. 70. REST OF APAC PHARMACEUTICAL DRUG DELIVERY SYSTEM MARKET VALUE, BY END-USER, 2020-2026 (USD BILLION)
CHART. 71. REST OF WORLD PHARMACEUTICAL DRUG DELIVERY SYSTEM MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2020-2026 (USD BILLION)
CHART. 72. REST OF WORLD PHARMACEUTICAL DRUG DELIVERY SYSTEM MARKET VALUE, BY APPLICATION, 2020-2026 (USD BILLION)
CHART. 73. REST OF WORLD PHARMACEUTICAL DRUG DELIVERY SYSTEM MARKET VALUE, BY END-USER, 2020-2026 (USD BILLION)
CHART. 1. GLOBAL PHARMACEUTICAL DRUG DELIVERY SYSTEM MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2020-2026 (USD BILLION)
CHART. 2. GLOBAL PHARMACEUTICAL DRUG DELIVERY SYSTEM MARKET VALUE FOR ORAL DRUG DELIVERY, BY GEOGRAPHY, 2020-2026 (USD BILLION)
CHART. 3. GLOBAL PHARMACEUTICAL DRUG DELIVERY SYSTEM MARKET VALUE FOR PULMONARY DRUG DELIVERY, BY GEOGRAPHY, 2020-2026 (USD BILLION)
CHART. 4. GLOBAL PHARMACEUTICAL DRUG DELIVERY SYSTEM MARKET VALUE FOR INJECTABLE DRUG DELIVERY, BY GEOGRAPHY, 2020-2026 (USD BILLION)
CHART. 5. GLOBAL PHARMACEUTICAL DRUG DELIVERY SYSTEM MARKET VALUE FOR OCULAR DRUG DELIVERY, BY GEOGRAPHY, 2020-2026 (USD BILLION)
CHART. 6. GLOBAL PHARMACEUTICAL DRUG DELIVERY SYSTEM MARKET VALUE FOR NASAL DRUG DELIVERY, BY GEOGRAPHY, 2020-2026 (USD BILLION)
CHART. 7. GLOBAL PHARMACEUTICAL DRUG DELIVERY SYSTEM MARKET VALUE FOR TOPICAL DRUG DELIVERY, BY GEOGRAPHY, 2020-2026 (USD BILLION)
CHART. 8. GLOBAL PHARMACEUTICAL DRUG DELIVERY SYSTEM MARKET VALUE FOR IMPLANTABLE DRUG DELIVERY, BY GEOGRAPHY, 2020-2026 (USD BILLION)
CHART. 9. GLOBAL PHARMACEUTICAL DRUG DELIVERY SYSTEM MARKET VALUE FOR TRANSMUCOSAL DRUG DELIVERY, BY GEOGRAPHY, 2020-2026 (USD BILLION)
CHART. 10. GLOBAL PHARMACEUTICAL DRUG DELIVERY SYSTEM MARKET VALUE, BY APPLICATION, 2020-2026 (USD BILLION)
CHART. 11. GLOBAL PHARMACEUTICAL DRUG DELIVERY SYSTEM MARKET VALUE FOR INFECTIOUS DISEASES, BY GEOGRAPHY, 2020-2026 (USD BILLION)
CHART. 12. GLOBAL PHARMACEUTICAL DRUG DELIVERY SYSTEM MARKET VALUE FOR CANCER, BY GEOGRAPHY, 2020-2026 (USD BILLION)
CHART. 13. GLOBAL PHARMACEUTICAL DRUG DELIVERY SYSTEM MARKET VALUE FOR CARDIOVASCULAR DISEASES, BY GEOGRAPHY, 2020-2026 (USD BILLION)
CHART. 14. GLOBAL PHARMACEUTICAL DRUG DELIVERY SYSTEM MARKET VALUE FOR DIABETES, BY GEOGRAPHY, 2020-2026 (USD BILLION)
CHART. 15. GLOBAL PHARMACEUTICAL DRUG DELIVERY SYSTEM MARKET VALUE FOR RESPIRATORY DISEASES, BY GEOGRAPHY, 2020-2026 (USD BILLION)
CHART. 16. GLOBAL PHARMACEUTICAL DRUG DELIVERY SYSTEM MARKET VALUE FOR CENTRAL NERVOUS SYSTEM DISORDERS, BY GEOGRAPHY, 2020-2026 (USD BILLION)
CHART. 17. GLOBAL PHARMACEUTICAL DRUG DELIVERY SYSTEM MARKET VALUE FOR AUTOIMMUNE DISEASES, BY GEOGRAPHY, 2020-2026 (USD BILLION)
CHART. 18. GLOBAL PHARMACEUTICAL DRUG DELIVERY SYSTEM MARKET VALUE, BY END-USER, 2020-2026 (USD BILLION)
CHART. 19. GLOBAL PHARMACEUTICAL DRUG DELIVERY SYSTEM MARKET VALUE FOR HOSPITALS, 2020-2026 (USD BILLION)
CHART. 20. GLOBAL PHARMACEUTICAL DRUG DELIVERY SYSTEMMARKET VALUE FOR HOME CARE SETTINGS, BY GEOGRAPHY, 2020-2026 (USD BILLION)
CHART. 21. GLOBAL PHARMACEUTICAL DRUG DELIVERY SYSTEM MARKET VALUE FOR AMBULATORY SURVEY CENTERS, BY GEOGRAPHY, 2020-2026 (USD BILLION)
CHART. 22. GLOBAL PHARMACEUTICAL DRUG DELIVERY SYSTEM MARKET VALUE FOR DIAGNOSTIC CENTERS, BY GEOGRAPHY, 2020-2026 (USD BILLION)
CHART. 23. NORTH AMERICA PHARMACEUTICAL DRUG DELIVERY SYSTEM MARKET VALUE, BY COUNTRY, 2020-2026 (USD BILLION)
CHART. 24. NORTH AMERICA PHARMACEUTICAL DRUG DELIVERY SYSTEM MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2020-2026 (USD BILLION)
CHART. 25. NORTH AMERICA PHARMACEUTICAL DRUG DELIVERY SYSTEM MARKET VALUE, BY APPLICATION, 2020-2026 (USD BILLION)
CHART. 26. NORTH AMERICA PHARMACEUTICAL DRUG DELIVERY SYSTEM MARKET VALUE, BY END-USER, 2020-2026 (USD BILLION)
CHART. 27. U.S PHARMACEUTICAL DRUG DELIVERY SYSTEM MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2020-2026 (USD BILLION)
CHART. 28. U.S PHARMACEUTICAL DRUG DELIVERY SYSTEM MARKET VALUE, BY APPLICATION, 2020-2026 (USD BILLION)
CHART. 29. U.S PHARMACEUTICAL DRUG DELIVERY SYSTEM MARKET VALUE, BY END-USER, 2020-2026 (USD BILLION)
CHART. 30. CANADA PHARMACEUTICAL DRUG DELIVERY SYSTEM MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2020-2026 (USD BILLION)
CHART. 31. CANADA PHARMACEUTICAL DRUG DELIVERY SYSTEM MARKET VALUE, BY APPLICATION, 2020-2026 (USD BILLION)
CHART. 32. CANADA PHARMACEUTICAL DRUG DELIVERY SYSTEM MARKET VALUE, BY END-USER, 2020-2026 (USD BILLION)
CHART. 33. EUROPE PHARMACEUTICAL DRUG DELIVERY SYSTEM MARKET VALUE, BY COUNTRY, 2020-2026 (USD BILLION)
CHART. 34. EUROPE PHARMACEUTICAL DRUG DELIVERY SYSTEM MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2020-2026 (USD BILLION)
CHART. 35. EUROPE PHARMACEUTICAL DRUG DELIVERY SYSTEM MARKET VALUE, BY APPLICATION, 2020-2026 (USD BILLION)
CHART. 36. EUROPE PHARMACEUTICAL DRUG DELIVERY SYSTEM MARKET VALUE, END-USER, 2020-2026 (USD BILLION)
CHART. 37. GERMANY PHARMACEUTICAL DRUG DELIVERY SYSTEM MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2020-2026 (USD BILLION)
CHART. 38. GERMANY PHARMACEUTICAL DRUG DELIVERY SYSTEM MARKET VALUE, BY APPLICATION, 2020-2026 (USD BILLION)
CHART. 39. GERMANY PHARMACEUTICAL DRUG DELIVERY SYSTEM MARKET VALUE, BY END-USER, 2020-2026 (USD BILLION)
CHART. 40. U.K PHARMACEUTICAL DRUG DELIVERY SYSTEM MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2020-2026 (USD BILLION)
CHART. 41. U.K PHARMACEUTICAL DRUG DELIVERY SYSTEM MARKET VALUE, BY APPLICATION, 2020-2026 (USD BILLION)
CHART. 42. U.K PHARMACEUTICAL DRUG DELIVERY SYSTEM MARKET VALUE, BY END-USER, 2020-2026 (USD BILLION)
CHART. 43. FRANCE PHARMACEUTICAL DRUG DELIVERY SYSTEM MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2020-2026 (USD BILLION)
CHART. 44. FRANCE PHARMACEUTICAL DRUG DELIVERY SYSTEM MARKET VALUE, BY APPLICATION, 2020-2026 (USD BILLION)
CHART. 45. FRANCE PHARMACEUTICAL DRUG DELIVERY SYSTEM MARKET VALUE, BY END-USER, 2020-2026 (USD BILLION)
CHART. 46. ITALY PHARMACEUTICAL DRUG DELIVERY SYSTEM MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2020-2026 (USD BILLION)
CHART. 47. ITALY PHARMACEUTICAL DRUG DELIVERY SYSTEM MARKET VALUE, BY APPLICATION, 2020-2026 (USD BILLION)
CHART. 48. ITALY PHARMACEUTICAL DRUG DELIVERY SYSTEM MARKET VALUE, BY END-USER, 2020-2026 (USD BILLION)
CHART. 49. SPAIN PHARMACEUTICAL DRUG DELIVERY SYSTEM MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2020-2026 (USD BILLION)
CHART. 50. SPAIN PHARMACEUTICAL DRUG DELIVERY SYSTEM MARKET VALUE, BY APPLICATION, 2020-2026 (USD BILLION)
CHART. 51. SPAIN PHARMACEUTICAL DRUG DELIVERY SYSTEM MARKET VALUE, BY END-USER, 2020-2026 (USD BILLION)
CHART. 52. ROE PHARMACEUTICAL DRUG DELIVERY SYSTEM MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2020-2026 (USD BILLION)
CHART. 53. ROE PHARMACEUTICAL DRUG DELIVERY SYSTEM MARKET VALUE, BY APPLICATION, 2020-2026 (USD BILLION)
CHART. 54. ROE PHARMACEUTICAL DRUG DELIVERY SYSTEM MARKET VALUE, BY END-USER, 2020-2026 (USD BILLION)
CHART. 55. ASIA PACIFC PHARMACEUTICAL DRUG DELIVERY SYSTEM MARKET VALUE, BY COUNTRY, 2020-2026 (USD BILLION)
CHART. 56. ASIA PACIFC PHARMACEUTICAL DRUG DELIVERY SYSTEM MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2020-2026 (USD BILLION)
CHART. 57. ASIA PACIFC PHARMACEUTICAL DRUG DELIVERY SYSTEM MARKET VALUE, BY APPLICATION, 2020-2026 (USD BILLION)
CHART. 58. ASIA PACIFC PHARMACEUTICAL DRUG DELIVERY SYSTEM MARKET VALUE, BY END-USER, 2020-2026 (USD BILLION)
CHART. 59. CHINA PHARMACEUTICAL DRUG DELIVERY SYSTEM MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2020-2026 (USD BILLION)
CHART. 60. CHINA PHARMACEUTICAL DRUG DELIVERY SYSTEM MARKET VALUE, BY APPLICATION, 2020-2026 (USD BILLION)
CHART. 61. CHINA PHARMACEUTICAL DRUG DELIVERY SYSTEM MARKET VALUE, BY END-USER, 2020-2026 (USD BILLION)
CHART. 62. INDIA PHARMACEUTICAL DRUG DELIVERY SYSTEM MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2020-2026 (USD BILLION)
CHART. 63. INDIA PHARMACEUTICAL DRUG DELIVERY SYSTEM MARKET VALUE, BY APPLICATION, 2020-2026 (USD BILLION)
CHART. 64. INDIA PHARMACEUTICAL DRUG DELIVERY SYSTEM MARKET VALUE, BY END-USER, 2020-2026 (USD BILLION)
CHART. 65. JAPAN PHARMACEUTICAL DRUG DELIVERY SYSTEM MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2020-2026 (USD BILLION)
CHART. 66. JAPAN PHARMACEUTICAL DRUG DELIVERY SYSTEM MARKET VALUE, BY APPLICATION, 2020-2026 (USD BILLION)
CHART. 67. JAPAN PHARMACEUTICAL DRUG DELIVERY SYSTEM MARKET VALUE, BY END-USER, 2020-2026 (USD BILLION)
CHART. 68. REST OF APAC PHARMACEUTICAL DRUG DELIVERY SYSTEM MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2020-2026 (USD BILLION)
CHART. 69. REST OF APAC PHARMACEUTICAL DRUG DELIVERY SYSTEM MARKET VALUE, BY APPLICATION, 2020-2026 (USD BILLION)
CHART. 70. REST OF APAC PHARMACEUTICAL DRUG DELIVERY SYSTEM MARKET VALUE, BY END-USER, 2020-2026 (USD BILLION)
CHART. 71. REST OF WORLD PHARMACEUTICAL DRUG DELIVERY SYSTEM MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2020-2026 (USD BILLION)
CHART. 72. REST OF WORLD PHARMACEUTICAL DRUG DELIVERY SYSTEM MARKET VALUE, BY APPLICATION, 2020-2026 (USD BILLION)
CHART. 73. REST OF WORLD PHARMACEUTICAL DRUG DELIVERY SYSTEM MARKET VALUE, BY END-USER, 2020-2026 (USD BILLION)
